ELEDON PHARMACEUTICALS INC (ELDN)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
What ELEDON PHARMACEUTICALS INC does
Eledon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel drug candidates to treat serious diseases. The company's primary efforts have been devoted to advancing tegoprubart through preclinical and clinical development, with no approved products for commercial sale to date. Eledon is in the early stages of clinical development and has financed its operations primarily through sales of equity securities, with all resources focused on research and development activities.
Themes: autoimmune diseases, organ transplantation, clinical-stage biotech, immunology
Fundamentals
- Price$3.41 as of 2026-08-24 close
- Market cap$277M as of 2026-08-24
- 1-year return+31.2% 2025-08-22 close $2.60 → 2026-08-24 close $3.41
- P/En/a earnings data not available
- ROE-72.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.32 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How ELDN compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ELEDON PHARMACEUTICALS INC looks technically
ELEDON PHARMACEUTICALS INC (ELDN) is trading 17.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 91 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day low about 19 trading days ago. It is 25.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 17.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.72 | $3.72 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.91 | $2.91 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 3.88. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 91 trading days ago — a "golden cross", a bullish long-term signal | 91 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 14.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 40.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($3.27 to $3.88) — its "stochastic" reading is 24 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 23.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.60 | $4.60 |
|---|---|---|
| From the 52-week high | it is 25.9% below its 52-week high (its highest price of the past year) | -25.9% |
| Above the 52-week low | it is 152.6% above its 52-week low (its lowest price of the past year) | +152.6% |
| Below the 52-week high | it is 25.9% below its highest point of the past year | 25.9% |
| Since a 20-day breakout | it made a new 20-day low about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day low about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $4860.00 (set on 2014-09-17) | $4860.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.39 to $4.36), and it has recovered well over two thirds of its fall from last year’s high — 68% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.23 to $3.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 17 days, so it is a narrow thing to be measuring a retracement against. | 68.0% |
| From the all-time high | it is 99.9% below its all-time high | -99.9% |
| Nearest price level | it is trading 2.8% below a resistance level at $3.51 — a price it turned at three times since 2025-03-11, most recently on 2025-08-06. Since 2024-08-26 it has 9 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.8% |
| All-time low | its lowest closing price on record is $1.07 (set on 2023-11-09) | $1.07 |
| Above the all-time low | it is 218.7% above its all-time low | +218.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 89% of it) | 11th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1953 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1953 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.27 and $3.79 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.27 – $3.53 – $3.79 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 2.6 daily ranges above its 200-day average price (17.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.23× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-24 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.6% |
|---|---|---|
| Gap filled | a 2.7% gap down opened on 2026-08-14 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 4 sessions in a row, a -5.8% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 4 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.1 percentage points (the stock lost 4.7% while the market gained 3.3%) | -8.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 14.7 percentage points (the stock lost 12.3% while the market gained 2.4%) | -14.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 28.1 percentage points (the stock gained 39.2% while the market gained 11.1%) | +28.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 12.8 percentage points (the stock gained 31.2% while the market gained 18.3%) | +12.8% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.5% of the share price. | -12.2% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 3% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.32 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +2.6% |
|---|
Price levels it has turned at before
ELDN last closed at $3.41 on 2026-08-24. Since 2024-08-26 it has turned at 9 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.51 | Resistance | 2.8% above the last close | turned there three times · 2025-03-11 to 2025-08-06 |
| $3.27 | Support | 4.1% below the last close | turned there five times · 2025-05-27 to 2026-07-31 |
| $3.17 | Support | 7.0% below the last close | turned there twice · 2026-03-10 to 2026-03-23 |
| $2.90 | Support | 14.8% below the last close | turned there twice · 2025-06-05 to 2025-07-29 |
| $3.95 | Resistance | 15.8% above the last close | turned there twice · 2024-12-20 to 2025-07-24 |
| $4.06 | Resistance | 19.1% above the last close | turned there twice · 2025-07-15 to 2026-05-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $3.88.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $2.30 and $2.90 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $3.88.
This reading has stood for 6 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · beating the market · Printed a hammer candle after a decline | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$9.00 range $7.00 – $12.00; median $8.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ELDN
- Consensus EPS estimate-$0.19 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no approved products and no revenue from product sales; tegoprubart and future candidates may not be successfully developed or approved for commercialization","Significant ongoing losses and negative cash flows since inception; accumulated deficit of $440.2 million as of Q1 2026 with no path to profitability established","Dependence on raising additional capital to fund drug development, manufacturing, regulatory approvals, and commercialization; equity dilution from ongoing fundraising and warrant exercises"]
What changed in the latest 10-Q
AI-assisted comparison of ELDN's 10-Q filed 2026-05-13 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ELDN — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ELDN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,612,136
- Reported value $17,285,379
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ELDN had 6,213,318 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ELDN had 7.65% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.49 days to cover at the same settlement.
- Reported short interest (shares) 6,213,318
- Short interest (% of shares outstanding) 7.65%
- Prior settlement (shares) 5,522,678
- Reported change 12.51%
- Days to cover (reported) 6.49
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNY)
- Vertex Pharmaceuticals (VRTX)
- Alexion Pharmaceuticals (AstraZeneca - AZN)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ELDN vs…
ELEDON PHARMACEUTICALS INC is found in…
Frequently asked questions
What does ELEDON PHARMACEUTICALS INC (ELDN) do?
Eledon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel drug candidates to treat serious diseases. The company's primary efforts have been devoted to advancing tegoprubart through preclinical and clinical development, with no approved products for commercial sale to date.
What sector is ELEDON PHARMACEUTICALS INC (ELDN) in?
ELEDON PHARMACEUTICALS INC (ELDN) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceuticals. It trades on NASDAQ.
Who are ELEDON PHARMACEUTICALS INC's (ELDN) competitors?
Notable peers of ELEDON PHARMACEUTICALS INC (ELDN) include Sanofi, Vertex Pharmaceuticals, Alexion Pharmaceuticals (AstraZeneca - AZN) and Novartis. This peer set is informational only — not financial advice.
Is ELEDON PHARMACEUTICALS INC (ELDN) overbought or oversold right now?
ELEDON PHARMACEUTICALS INC (ELDN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ELDN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.